Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30058354HIVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS30058355HIVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20000364HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20002291HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20002044HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20001275HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20066250HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20057494HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20057195HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TVIS20017939HPVENSG00000114670.14protein_codingNEK11NoNo79858E9PHI8
Q8NG66
TCGA Plot Options
Drug Information
GeneNEK11
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0004758
UniProt IDQ8NG66
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830